psoriatic arthritis

Roflumilast Therapeutic Cheat Sheet
Roflumilast
by Adam Rosenfeld, MD on
Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o …
Apremilast Therapeutic Cheat Sheet
apremilast
by Alexis Carrington, MD on
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …
Upadacitinib Therapeutic Cheat Sheet
Upadacitinib
by Alexis Carrington, MD on
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat  rheumatoid arthritis and psoriatic arthritis, but  was recently FDA approved i …
Translating Psoriasis Guidelines into Practice
psoriasis guidelines
by Mojgan Hosseinipour, DO, FAAD on
Before we dive into our discussion, let’s outline the Guideline-Based Approach to Treatment Selection. The International Psoriasis Council has divided psoriasis treatment classification into 2 groups: Patients who are a candidate for topical therapy, or Patients who are a candidate for systemic therapy Candidates for systemic therapy must meet at least 1 of the following …
Pediatric Verrucous Psoriasis: A Case Report in a Pediatric Patient
Pediatric Verrucous Psoriasis
by NEXT STEPS IN DERM TEAM on
Verrucous psoriasis (VP) is a rare histologic variant of psoriasis. To date, fewer than 40 cases have been reported, with pediatric cases representing an exceedingly small fraction. Treatment options are limited, and the disease is often refractory to conventional methods. Herein, JDD authors Samantha Sherkin OMS-IV, Christian Summa OMS-IV, David Crasto DO, Zackary Whitney DO, Lazlo Karai MD PhD,� …